德国阿达曼蒂亚德-贝赫切特病的流行病学和治疗:医疗索赔数据库研究。

IF 8.4 2区 医学 Q1 DERMATOLOGY
C C Zouboulis, J Borchert, J Diesing, R Heinrich, W Galetzka, J-P Medelnik, A Altenburg, A Feldhus, T Schönfelder
{"title":"德国阿达曼蒂亚德-贝赫切特病的流行病学和治疗:医疗索赔数据库研究。","authors":"C C Zouboulis, J Borchert, J Diesing, R Heinrich, W Galetzka, J-P Medelnik, A Altenburg, A Feldhus, T Schönfelder","doi":"10.1111/jdv.20489","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adamantiades-Behçet's disease (ABD) is a rare, chronic, relapsing, multisystem vasculitis, with a reported prevalence of 0.9 out of 100,000 population in Germany in 2012. However, more recent epidemiological data are lacking.</p><p><strong>Objectives: </strong>To estimate the prevalence and incidence of ABD in Germany and assess associated comorbidities and current treatment patterns.</p><p><strong>Methods: </strong>This retrospective cohort study used claims data from the anonymized Institute for Applied Health Research Berlin (InGef) research database. Cohorts were formed for the observation years 2016, 2017 and 2018, using data from 2013 to 2018 (allowing for a 3-year baseline period for incidence data). The study population included patients ≥18 years old with a diagnosis of ABD (ICD-10 diagnostic code M35.2), covered under the statutory health insurance system and in the InGef research database, with continuous insurance in the observation year and baseline period. We descriptively evaluated prevalence (≥2 outpatient ABD diagnoses in different quarters/≥1 main inpatient diagnosis in the observation year), incidence (no confirmed outpatient/inpatient diagnosis in the baseline period), comorbidities reported during the study and ABD-related medications.</p><p><strong>Results: </strong>We identified 300, 303 and 329 patients diagnosed with ABD in 2016, 2017 and 2018, respectively, with fewer than half (122/300 [40.7%], 127/303 [41.9%] and 150/329 [45.6%]) prescribed ≥1 disease-related medication. In the treated population, ABD prevalence was 3.9 (2016), 4.1 (2017) and 4.7 (2018) per 100,000 population; annual ABD incidence was 0.5 per 100,000 population in 2016 and 2017 and 0.6 per 100,000 population in 2018. The most commonly reported comorbidities in patients diagnosed with ABD were dorsalgia (an indicator of possible misdiagnosis), disorders of refraction and accommodation, and essential (primary) hypertension. Prednisolone, colchicine and azathioprine were the most commonly prescribed treatments for ABD, with approximately 15% of patients taking >1 medication for ABD.</p><p><strong>Conclusions: </strong>The reported data provide evidence that ABD remains a rare disease in Germany.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Epidemiology and treatment of Adamantiades-Behçet's disease in Germany: A healthcare claims database study.\",\"authors\":\"C C Zouboulis, J Borchert, J Diesing, R Heinrich, W Galetzka, J-P Medelnik, A Altenburg, A Feldhus, T Schönfelder\",\"doi\":\"10.1111/jdv.20489\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Adamantiades-Behçet's disease (ABD) is a rare, chronic, relapsing, multisystem vasculitis, with a reported prevalence of 0.9 out of 100,000 population in Germany in 2012. However, more recent epidemiological data are lacking.</p><p><strong>Objectives: </strong>To estimate the prevalence and incidence of ABD in Germany and assess associated comorbidities and current treatment patterns.</p><p><strong>Methods: </strong>This retrospective cohort study used claims data from the anonymized Institute for Applied Health Research Berlin (InGef) research database. Cohorts were formed for the observation years 2016, 2017 and 2018, using data from 2013 to 2018 (allowing for a 3-year baseline period for incidence data). The study population included patients ≥18 years old with a diagnosis of ABD (ICD-10 diagnostic code M35.2), covered under the statutory health insurance system and in the InGef research database, with continuous insurance in the observation year and baseline period. We descriptively evaluated prevalence (≥2 outpatient ABD diagnoses in different quarters/≥1 main inpatient diagnosis in the observation year), incidence (no confirmed outpatient/inpatient diagnosis in the baseline period), comorbidities reported during the study and ABD-related medications.</p><p><strong>Results: </strong>We identified 300, 303 and 329 patients diagnosed with ABD in 2016, 2017 and 2018, respectively, with fewer than half (122/300 [40.7%], 127/303 [41.9%] and 150/329 [45.6%]) prescribed ≥1 disease-related medication. In the treated population, ABD prevalence was 3.9 (2016), 4.1 (2017) and 4.7 (2018) per 100,000 population; annual ABD incidence was 0.5 per 100,000 population in 2016 and 2017 and 0.6 per 100,000 population in 2018. The most commonly reported comorbidities in patients diagnosed with ABD were dorsalgia (an indicator of possible misdiagnosis), disorders of refraction and accommodation, and essential (primary) hypertension. Prednisolone, colchicine and azathioprine were the most commonly prescribed treatments for ABD, with approximately 15% of patients taking >1 medication for ABD.</p><p><strong>Conclusions: </strong>The reported data provide evidence that ABD remains a rare disease in Germany.</p>\",\"PeriodicalId\":17351,\"journal\":{\"name\":\"Journal of the European Academy of Dermatology and Venereology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.4000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the European Academy of Dermatology and Venereology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/jdv.20489\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the European Academy of Dermatology and Venereology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jdv.20489","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:adamantiades - behet病(ABD)是一种罕见的慢性、复发性、多系统血管炎,据报道,2012年德国每10万人中有0.9人患有此病。然而,缺乏更近期的流行病学数据。目的:评估ABD在德国的患病率和发病率,并评估相关的合并症和当前的治疗模式。方法:这项回顾性队列研究使用来自匿名柏林应用健康研究所(InGef)研究数据库的索赔数据。使用2013年至2018年的数据(允许发病率数据的3年基线期),在2016年、2017年和2018年观察年形成队列。研究人群包括年龄≥18岁,诊断为ABD (ICD-10诊断代码M35.2)的患者,纳入法定健康保险制度和InGef研究数据库,在观察年和基线期持续保险。我们描述性地评估了患病率(不同季度门诊ABD诊断≥2例/观察年内主要住院诊断≥1例)、发病率(基线期未确诊门诊/住院诊断)、研究期间报告的合并症和ABD相关药物。结果:我们在2016年、2017年和2018年分别发现了300例、303例和329例诊断为ABD的患者,其中不到一半(122/300[40.7%]、127/303[41.9%]和150/329[45.6%])处方≥1种疾病相关药物。在接受治疗的人群中,ABD患病率分别为每10万人3.9(2016年)、4.1(2017年)和4.7(2018年);2016年和2017年ABD年发病率为每10万人0.5例,2018年为每10万人0.6例。被诊断为ABD的患者中最常见的合并症是背痛症(可能误诊的一个指标)、屈光和调节障碍以及原发性高血压。强的松龙、秋水仙碱和硫唑嘌呤是ABD最常用的处方治疗方法,大约15%的患者服用bbb1药物治疗ABD。结论:报道的数据表明,ABD在德国仍然是一种罕见的疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Epidemiology and treatment of Adamantiades-Behçet's disease in Germany: A healthcare claims database study.

Background: Adamantiades-Behçet's disease (ABD) is a rare, chronic, relapsing, multisystem vasculitis, with a reported prevalence of 0.9 out of 100,000 population in Germany in 2012. However, more recent epidemiological data are lacking.

Objectives: To estimate the prevalence and incidence of ABD in Germany and assess associated comorbidities and current treatment patterns.

Methods: This retrospective cohort study used claims data from the anonymized Institute for Applied Health Research Berlin (InGef) research database. Cohorts were formed for the observation years 2016, 2017 and 2018, using data from 2013 to 2018 (allowing for a 3-year baseline period for incidence data). The study population included patients ≥18 years old with a diagnosis of ABD (ICD-10 diagnostic code M35.2), covered under the statutory health insurance system and in the InGef research database, with continuous insurance in the observation year and baseline period. We descriptively evaluated prevalence (≥2 outpatient ABD diagnoses in different quarters/≥1 main inpatient diagnosis in the observation year), incidence (no confirmed outpatient/inpatient diagnosis in the baseline period), comorbidities reported during the study and ABD-related medications.

Results: We identified 300, 303 and 329 patients diagnosed with ABD in 2016, 2017 and 2018, respectively, with fewer than half (122/300 [40.7%], 127/303 [41.9%] and 150/329 [45.6%]) prescribed ≥1 disease-related medication. In the treated population, ABD prevalence was 3.9 (2016), 4.1 (2017) and 4.7 (2018) per 100,000 population; annual ABD incidence was 0.5 per 100,000 population in 2016 and 2017 and 0.6 per 100,000 population in 2018. The most commonly reported comorbidities in patients diagnosed with ABD were dorsalgia (an indicator of possible misdiagnosis), disorders of refraction and accommodation, and essential (primary) hypertension. Prednisolone, colchicine and azathioprine were the most commonly prescribed treatments for ABD, with approximately 15% of patients taking >1 medication for ABD.

Conclusions: The reported data provide evidence that ABD remains a rare disease in Germany.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.70
自引率
8.70%
发文量
874
审稿时长
3-6 weeks
期刊介绍: The Journal of the European Academy of Dermatology and Venereology (JEADV) is a publication that focuses on dermatology and venereology. It covers various topics within these fields, including both clinical and basic science subjects. The journal publishes articles in different formats, such as editorials, review articles, practice articles, original papers, short reports, letters to the editor, features, and announcements from the European Academy of Dermatology and Venereology (EADV). The journal covers a wide range of keywords, including allergy, cancer, clinical medicine, cytokines, dermatology, drug reactions, hair disease, laser therapy, nail disease, oncology, skin cancer, skin disease, therapeutics, tumors, virus infections, and venereology. The JEADV is indexed and abstracted by various databases and resources, including Abstracts on Hygiene & Communicable Diseases, Academic Search, AgBiotech News & Information, Botanical Pesticides, CAB Abstracts®, Embase, Global Health, InfoTrac, Ingenta Select, MEDLINE/PubMed, Science Citation Index Expanded, and others.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信